- The National Cancer Institute awards Telik (OTCQB:TELK +31.9%) a $1.5M grant to fund the second phase of project to develop a Positron Emission Tomography (PET) imaging agent for the detection and assessment of pancreatic cancer. The agent is based on the company's radiolabeled 5B1 antibody to the sialyl-Lewis antigen.